Current evidence suggests that novel targeted therapies exhibit enhanced efficacy and acceptable safety profiles compared with traditional later-line treatments for advanced NSCLC with EGFR ex20ins. This evidence concerns the gene EGFR and non-small cell lung carcinoma.